Cardiotoxicity of Molecularly Targeted Agents

Publisher： Bentham Science Publishers

E-ISSN： 1875-6557|7|4|221-233

ISSN： 1573-403X

Source： Current Cardiology Reviews, Vol.7, Iss.4, 2011-11, pp. : 221-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone

By  

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 303-309

Karger

Access to resources Recommend Favorite

Are targeted contrast agents realistically going to reach the clinic? Recent regulatory experience with targeted MRI contrast agents

By Dzik-Jurasz A  

British Journal of Radiology, Vol. 79, Iss. 947, 2006-11 ,pp. : 870-872

British Institute of Radiology

Access to resources Recommend Favorite

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives

By  

Liver Cancer, Vol. 6, Iss. 2, 2016-12 ,pp. : 101-112

Karger

Access to resources Recommend Favorite

Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?

By  

Liver Cancer, Vol. 1, Iss. 2, 2012-09 ,pp. : 59-60

Karger

Access to resources Recommend Favorite

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma

By  

Journal Of Cachexia Sarcopenia And Muscle, Vol. 6, Iss. 3, 2015-09 ,pp. : 222-230

John Wiley & Sons Inc

Access to resources Recommend Favorite